These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 11319721

  • 1. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG, Pittner R, Jodka C, Smith P, Young A.
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 4. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
    Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K.
    Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
    [Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
    Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B.
    Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol.
    Zawalich WS, Zawalich KC.
    Metabolism; 1996 Feb; 45(2):273-8. PubMed ID: 8596502
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of Langerhans.
    Sreenan SK, Mittal AA, Dralyuk F, Pugh WL, Polonsky KS, Roe MW.
    Metabolism; 2000 Dec; 49(12):1579-87. PubMed ID: 11145120
    [Abstract] [Full Text] [Related]

  • 8. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
    Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B.
    Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
    [Abstract] [Full Text] [Related]

  • 9. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R.
    Biochim Biophys Acta; 1991 Feb 19; 1091(3):356-63. PubMed ID: 1705823
    [Abstract] [Full Text] [Related]

  • 10. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
    Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM.
    Diabetologia; 1999 Jan 19; 42(1):45-50. PubMed ID: 10027577
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
    Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR.
    Diabetes; 1999 Jan 19; 48(1):86-93. PubMed ID: 9892226
    [Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M, Ahrén B.
    Horm Metab Res; 2004 Jan 19; 36(11-12):795-803. PubMed ID: 15655711
    [Abstract] [Full Text] [Related]

  • 13. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan 19; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH.
    J Clin Endocrinol Metab; 2002 Mar 19; 87(3):1239-46. PubMed ID: 11889194
    [Abstract] [Full Text] [Related]

  • 18. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.
    Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH.
    Diabetes; 1995 May 19; 44(5):495-500. PubMed ID: 7729605
    [Abstract] [Full Text] [Related]

  • 19. Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets.
    Colombo M, Gregersen S, Xiao J, Hermansen K.
    Pancreas; 2003 Aug 19; 27(2):161-6. PubMed ID: 12883265
    [Abstract] [Full Text] [Related]

  • 20. Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice.
    Ahrén B, Lindskog S, van Dijk G, Scheurink AJ, Steffens AB.
    Endocr Res; 1995 Aug 19; 21(3):583-94. PubMed ID: 7588428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.